Skip to content

Efficacy and Safety of Gonioscopy Assisted Transluminal Trabeculotomy in Patients with Primary Open-angle Glaucoma and Cataract.

Efficacy and Safety of Gonioscopy Assisted Transluminal Trabeculotomy in Patients with Primary Open-angle Glaucoma and Cataract - a Randomized Clinical Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06865235
Enrollment
90
Registered
2025-03-07
Start date
2024-05-07
Completion date
2028-02-29
Last updated
2025-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open Angle Glaucoma (OAG)

Keywords

Open angle glaucoma, Cataract, OAG, Goniotomy assisted transluminal trabeculotomy, GATT, trabeculotomy, Goniotomy, hemi-gatt

Brief summary

Prospective, randomized, , double-blind, clinical trial, comparing the variation of intraocular pressure (IOP) of patients with mild or moderate primary open-angle glaucoma (OAG) and cataract divided into three groups. All study participants should be treated for the pathology with one or more hypotensive medications or, regardless of the number of drugs, when IOP is greater than 20 mmHg and less than 26 mmHg. The two-year follow-up should also compare the reduction in the number of medications used, reoperation rate, adverse effects, visual acuity, endothelial loss, induction of astigmatism, variation in IOP according to axial diameter of the eye, anterior chamber and age, in addition to the existence of change in the quality of life of patients in the postoperative period

Interventions

PROCEDURE360º goniotomy assisted transluminal trabeculotomy

Open the Schlemm Canal for 360º with a polipropilen 5-0 suture via trabecular meshwork.

PROCEDUREPhacoemulsification

Cataract Surgery

PROCEDURE180º gonioscopy assisted transluminal trabeculotomy

Open the Schlemm Canal for 180º with a polipropilen 5-0 suture via trabecular meshwork.

Sponsors

Hospital Evangélico de Belo Horizonte
CollaboratorUNKNOWN
Faculdade de Ciências Médicas de Minas Gerais
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

The researcher who measures IOP

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 40 years or older, * Previously included in the glaucoma departments of the participating institutions, * Indication for cataract surgery, diagnosed by clinical examination with visual acuity (VA) equal to or worse than 20/40, * Primary Open Angle Glaucoma (POAG), determined by the presence of typical visual field (VF) defects and/or by the aspect of the optic nerve observed at fundoscopy or retinography (increased vertical optical excavation with thinning of the neural rhyme, asymmetry of the cup/disc ratio greater than 0.2, localized loss (notch) or defect in the retinal nerve fiber layer (Hoyt)). * APIC classification with amplitude greater/equal to 2 and pigmentation less than 4 on gonioscopy. * Intraocular pressure (IOP) less than or equal to 25 mmHg before washout of hypotensive eye drops. * IOP between 22 and 30 mmHg after washout of hypotensive eye drops or with a history of IOP greater than or equal to 21 mmHg in more than one previous care described in the medical record.

Exclusion criteria

Patients who have any of the following situations: * Severe glaucoma, determined according to the Hoddap-Parrish-Anderson criteria; * Axial diameter greater than 26 mm or less than 21.00 mm; * Endothelial count less than 1500 cc; * Pachymetry less than 480 or greater than 600 microns; * Patients undergoing some type of intraocular surgery or laser procedure in the preoperative period and/or after these procedures in the postoperative period; * Those who present some important per-operative complication during the study. * With high risk of progression, the so-called rapid progressors, who are patients with high IOPs even with the use of many medications, regardless of the severity of the nerve injury.

Design outcomes

Primary

MeasureTime frameDescription
Change in intraocular pressure (IOP) after surgery.From glaucoma medications washout to 2 years after the surgeryTo evaluate the change in intraocular pressure (IOP) after surgery, in patients with mild to moderate GPAA, undergoing phacoemulsification associated with gonioscopy assisted transluminal trabeculotomy by 180º (GATT 180º) or 360º (GATT 360º), and compare the results between the groups mentioned and with similar controls, who operated only on cataracts, in a period of up to two years.
Change in the number of glaucoma medications after surgery.From glaucoma medications washout to 2 years after the surgeryTo evaluate the change in the number of glaucoma medications applied after surgery, in patients with mild to moderate GPAA, undergoing phacoemulsification associated with gonioscopy assisted transluminal trabeculotomy by 180º (GATT 180º) or 360º (GATT 360º), and compare the results between the groups mentioned and with similar controls, who operated only on cataracts, in a period of up to two years.

Secondary

MeasureTime frameDescription
Survival AnalysisFrom glaucoma medications washout to 2 years after the surgeryEvaluate and compare the need for new glaucoma surgeries between the groups.
Prognostic factors of the surgeries.From glaucoma medications washout to 2 years after the surgeryEvaluate the association of IOP variation with axial eye length (AXL) in the groups.
Secundary changes in the eye after the surgeriesFrom glaucoma medications washout to 2 years after the surgeryEvaluate the visual acuity after the surgeries and compare between them.
Prognostic factors, and secundary changes in the eye after the surgeriesFrom glaucoma medications washout to 2 years after the surgeryEvaluate and compare the change in quality of life in and between the groups.

Countries

Brazil

Contacts

Primary ContactDaniel F Moura, MD
dfmoftalmo@gmail.com+5531991055860

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026